Truist raised the firm’s price target on Zimmer Biomet to $133 from $115 and keeps a Hold rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target lowered to $131 from $150 at Canaccord
- Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2023
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
- Zimmer Biomet price target raised to $125 from $120 at Morgan Stanley
- Zimmer Biomet price target lowered to $140 from $160 at JMP Securities